BioXcel Therapeutics has announced a clinical reprioritization, focusing on late-stage development of its agitation treatment ...

BioXcel Therapeutics (BTAI) stock gains as company shifts focus from commercial support for FDA-approved drug, Igalmi to lead ...

Patients undergoing complex gastrointestinal malignancy surgeries experience various challenges such as immune system ...

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia ...

Research on using sedation to improve patient tolerance to noninvasive ventilation (NIV) after traumatic chest injuries is ...

A recent study on the effects of commonly used anaesthetic and sedative drugs on cerebrospinal fluid flow and volume has uncovered significant findings regarding their impact on the brain's vital ...

Since Sunday, Tropical Storm Enteng (international name: Yagi) has brought rains and caused heavy flooding in Metro Manila and its neighboring cities, with Signal No. 2 raised in nine areas in Luzon.

Dexmedetomidine hydrochloride 1 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Pain. According to GlobalData, Phase III drugs for Pain have a 54% phase ...

The granted patent US11998529B2 outlines a method for treating agitation in human subjects using an oromucosal formulation of dexmedetomidine. The treatment protocol involves administering an initial ...

Reporting odds ratio (ROR), the proportional reporting ratio (PRR), and the Bayesian confidence propagation neural network (BCPNN) were employed to detect and assess adverse events associated with ...